1. In vitro studies on the role of recombinant human soluble thrombomodulin in the context of retinoic acid mediated APL differentiation syndrome.
- Author
-
Kojima S, Nishioka C, Chi S, Yokoyama A, and Ikezoe T
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Apoptosis, Biomarkers, Tumor, Cell Proliferation, Coculture Techniques, Disseminated Intravascular Coagulation chemically induced, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, In Vitro Techniques, Japan epidemiology, Male, Middle Aged, Prognosis, Recombinant Proteins genetics, Recombinant Proteins metabolism, Respiratory Distress Syndrome chemically induced, Retrospective Studies, Survival Rate, Thrombomodulin genetics, Tumor Cells, Cultured, p38 Mitogen-Activated Protein Kinases, Cell Differentiation drug effects, Disseminated Intravascular Coagulation epidemiology, Leukemia, Promyelocytic, Acute drug therapy, Respiratory Distress Syndrome epidemiology, Thrombomodulin metabolism, Tretinoin adverse effects
- Abstract
Recombinant human soluble thrombomodulin (rTM) is a newly developed anti-coagulant approved for treatment of disseminated intravascular coagulation (DIC) in Japan. rTM exerts anti-inflammatory and cytoprotective functions via its lectin-like and epidermal growth factor-like domains, respectively. In this study, we retrospectively reviewed the treatment of 21 consecutive patients with coagulopathy, complicated by acute promyelocytic leukemia (APL), with all-trans retinoic acid (ATRA) with or without combination with rTM. Surprisingly, none of the 14 rTM-treated patients developed retinoic acid (RA)-related differentiation syndrome (DS). The co-culture of vascular endothelial cell-derived EA.hy926 and APL-derived NB4 cells in the presence of RA increased production of tumor necrosis factor alpha (TNF-α) in culture media, in parallel with activation of p38 mitogen-activated protein kinase and increased levels of intracellular adhesion molecule 1 (ICAM1) in EA.hy926 cells. This was also associated with increased levels of the phosphorylated forms of VE-cadherin and enhanced vascular permeability of EA.hy926 monolayers. Importantly, addition of rTM to this co-culture system inhibited the RA-induced phosphorylation of p38 and VE-cadherin and decreased ICAM1 and vascular permeability in EA.hy926 cells, without a decrease inthe levels of TNF-α. Taken together, use of rTM may be a promising treatment strategy to prevent DS in APL patients who receive ATRA., (Copyright © 2017. Published by Elsevier Ltd.)
- Published
- 2017
- Full Text
- View/download PDF